Any feedback?
Please rate this page
(all_enzymes.php)
(0/150)

BRENDA support

2.3.1.48: histone acetyltransferase

This is an abbreviated version!
For detailed information about histone acetyltransferase, go to the full flat file.

Word Map on EC 2.3.1.48

Reaction

acetyl-CoA
+
[protein]-L-lysine
=
CoA
+
[protein]-N6-acetyl-L-lysine

Synonyms

AAPatA, acetyltransferase, histone, Ada2/Ada3/Gcn5 complex, AIB1, amino acid sensing acetyltransferase, AmiPatA, Amir 5672, ARD1, ARD1 acetyltransferase, arginine methyltransferase A, arginine methyltransferase B, arrest defective 1, arrest defective protein 1 acetyltransferase, At3g14980, ATAC2, ATase1, ATase2, cAMP-regulated protein lysine acetyltransferase, Cbp, CBP histone acetyltransferase, CBP/p300, chameau, circadian locomoter output cycles protein kaput, CLOCK, CREB binding protein, CREB-binding protein, CREBBP, east1, ELO3, ELONGATA3, elongator protein 3, ELP3, enhancer-of-asymmetric leaves-two1, Enok, EP300, Esa1, factor acetyltransferase, FAT, Gcn5, GCN5 family KAT, Gcn5 HAT, GCN5 lysine acetyltransferase, GCN5 N acetyltransferase 5, Gcn5 related N-acetyltransferase, GCN5-like acetyltransferase, GCN5-like enzyme, GCN5-related N-acetyltransferase, Gcn5/PCAF histone acetyltransferase, GCN5b, GCN5L2, general control non-derepressible 5, general control non-repressed protein5, general control nonderepressible 5, general control nonrepressed-protein 5, general control of amino acid synthesis 5, GNAT, GNAT-related histone acetyltransferase complex, GTF3C4, H4 lysine acetyltransferase, HAC1, HAG1, HAG3, HAG4, HAG5, HAM1, HAM2, hARD1, HAT, HAT-B, HAT-B complex, Hat1, Hat1p, Hat2, HatB3.I, HBO1, histone (H4 K16) acetyltransferase, histone acetokinase, histone acetyl transferase, histone acetylase, histone acetyltransferase, histone acetyltransferase 1, histone acetyltransferase AtGCN5, histone acetyltransferase B, histone acetyltransferase Tip60, histone acetyltransferase-1, histone acetyltransferases, histone H3 acetyltransferase, histone H4 acetyltransferase, histone H4 lysine 16 acetyltransferase, histone transacetylase, histone/protein lysine acetyltransferase, HIV-1 Tat-interactive protein, hMOF, Hpa2, Hpa3, human acetylase binding to ORC1, Idm1, K (lysine) acetyltransferase 8, K(lysine) acetyltransferase 8, KAT, KAT10, KAT11, KAT12, KAT13A, KAT13B, KAT13C, KAT13D, KAT2, Kat2A, KAT2A/GCN5, Kat2b, KAT3A, KAT3B, KAT4, KAT5, KAT6, KAT6A, KAT6B, KAT7, KAT8, KAT9, Lsy-12, lysine acetyltransferase, lysine acetyltransferase 2, lysine acetyltransferase 2A, lysine acetyltransferase 2B, lysine acetyltransferase 5, lysine acetyltransferase 8, lysine acetyltransferase complex, lysine acetyltransferase p300, lysine acetyltransferases, lysine-acetyltransferase, Mof, monocytic leukemia zinc finger, monocytic leukemia zinc finger protein, More, Morf, MORF histone acetyltransferase, MOZ, MOZ histone acetyltransferase, Moz related factor, Mst1, MtPat, Myb-binding protein 1A, MYBBP1A, MYST, MYST protein lysine acetyltransferase, MYST-related histone acetyltransferase complex, MYST1, MYST2, MYST3, MYST4, N(alpha)-acetyltransferase 10, N-acetyltransferase, N-terminal acetyltransferase, NAA10, NAT, NAT4, NCoA-1, NCoA-3, NCOAT, Nepsilon-lysine acetyltransferase, NuA4, NuA4 histone acetyltransferase, nuclear cytoplasmicO-GlcNAcase and acetyltransferase, nuclear receptor coactivator 1, nuclear receptor coactivator 3, nucleosome-histone acetyltransferase, Nut1, p/CAF, P/CAF histone acetyltransferase, p160, p300, p300 HAT, p300 histone acetyltransferase, p300/CBP, p300/CBP associated factor, p300/CBP histone acetyltransferase, P300/CBP-associated factor, p300/CBP-associated factor (pCAF), p300HAT, PA4534, Pat, PCAF, PCAF histone acetyltransferase, PF11_0192, PfGCN5, PfGCN5 HAT, Piccolo NuA4 complex, protein acetyl-transferase, protein acetyltransferase, Qkf, regulator of Ty1 transposition protein 109, RmtA, RmtB, RPD3, Rtt109, Rv0998, SAS complex, Sas2, Sas3, SRC1, SRC3, Sven 0867, SvePatA, TAF, TAF1, Tat interacting protein of 60 kDa, Tat-interactive protein, 60 kDa, TBP1, TFIIIC90, tGCN5, TgGCN5b, TgMYST-B, Tip60, tumor suppressor histone H3 lysine 23 acetyltransferase, type B histone acetyltransferase, YfmK, zMoz

ECTree

     2 Transferases
         2.3 Acyltransferases
             2.3.1 Transferring groups other than aminoacyl groups
                2.3.1.48 histone acetyltransferase

Inhibitors

Inhibitors on EC 2.3.1.48 - histone acetyltransferase

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(1E,4Z,6E)-1,7-bis(3-bromo-4-hydroxyphenyl)-5-hydroxyhepta-1,4,6-trien-3-one
-
cinnamoyl-II
(1E,4Z,6E)-5-hydroxy-1,7-bis(4-hydroxyphenyl)hepta-1,4,6-trien-3-one
-
BDMC
(1E,4Z,6E)-5-hydroxy-1-(4-hydroxy-3-methoxyphenyl)-7-(4-hydroxyphenyl)hepta-1,4,6-trien-3-one
-
DMC
(2-ethoxypropoxy)benzene
-
-
(2E)-2-(ethoxycarbonyl)heptadec-2-enoic acid
-
(2E)-2-(ethoxycarbonyl)hexadec-2-enoic acid
-
(2E)-2-acetylhexadec-2-enoic acid
-
-
(2E)-2-acetylpentadec-2-enoic acid
-
-
(2E,6E)-2,6-bis[(3,4-dihydroxyphenyl)methylidene]cyclohexan-1-one
89% residual activity at 0.1 mM
(2E,6E)-2,6-bis[(3,5-dibromo-4-hydroxyphenyl)methylidene]cyclohexan-1-one
(2E,6E)-2,6-bis[(3-bromophenyl)methylidene]cyclohexan-1-one
-
-
(2E,6E)-2,6-bis[(3-fluoro-4-hydroxyphenyl)methylidene]cyclohexan-1-one
6.3% residual activity at 0.1 mM
(2E,6E)-2,6-bis[(4-hydroxy-3,5-dimethylphenyl)methylidene]cyclohexan-1-one
-
-
(2E,6E)-2,6-bis[(4-hydroxy-3-iodophenyl)methylidene]cyclohexan-1-one
-
-
(2E,6E)-2,6-bis[(4-hydroxy-3-methylphenyl)methylidene]cyclohexan-1-one
3.0% residual activity at 0.1 mM
(2E,6E)-2,6-bis[(4-hydroxyphenyl)methylidene]cyclohexan-1-one
(2E,6E)-2,6-bis[(pyridin-3-yl)methylidene]cyclohexan-1-one
-
-
(2R)-2-[2-(4-[[(3-methyl-1-oxo-1,2-dihydrobenzo[f]quinazolin-9-yl)methyl]amino]phenyl)-2-oxoethyl]pentanedioic acid
-
(2R,3S)-4-methylidene-5-oxo-2-propyltetrahydrofuran-3-carboxylic acid
-
i.e. butyrolactone MB-3, a GCN5 inhibitor
(2S)-2-(5-[[(3-methyl-1-oxo-1,2-dihydrobenzo[f]quinazolin-9-yl)methyl]amino]-1-oxo-1,3-dihydro-2H-isoindol-2-yl)pentanedioic acid
ZINC36175770
(3-oxo-1,2-benzothiazol-2(3H)-yl)(phenyl)acetic acid
-
-
(3E,5E)-1-benzyl-3,5-bis[(3,4-dihydroxyphenyl)methylidene]piperidin-4-one
19.4% residual activity at 0.1 mM
(3E,5E)-3,5-bis[(3,4-dihydroxyphenyl)methylidene]-1-methylpiperidin-4-one
82.4% residual activity at 0.1 mM
(3E,5E)-3,5-bis[(3-bromo-4-hydroxyphenyl)methylidene]-4-oxopiperidin-1-ium
-
-
(3Z,5Z)-3,5-bis[(3-bromo-4-hydroxyphenyl)methylidene]thian-4-one
7.13% residual activity at 0.1 mM
(4-(4-((5-(4,5-dimethyl-2-nitrophenyl)furan-2-yl)methylene)-3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl) phenyl)phosphonic acid
-
(4-(4-((5-(4,5-dimethyl-2-nitrophenyl)furan-2-yl)methylene)-3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)phenyl)phosphonic acid
-
(4E)-2-(4-acetylphenyl)-4-[[5-(4,5-dimethyl-2-nitrophenyl)furan-2-yl]methylidene]-5-methyl-2,4-dihydro-3H-pyrazol-3-one
-
(5E)-1-(3-chloro-4-methylphenyl)-5-[(2E)-3-(furan-2-yl)prop-2-en-1-ylidene]-2-sulfanylidenedihydropyrimidine-4,6(1H,5H)-dione
-
(E)-4-(2-(5,6-dimethylbenzo[d]thiazol-2-yl)vinyl)-N,N-diethylbenzenesulfonamide
(E)-4-(2-(5-bromobenzo[d]thiazol-2-yl)vinyl)-N,N-diethylbenzenesulfonamide
(E)-4-(2-(5-chlorobenzo[d]thiazol-2-yl)vinyl)-N,N-diethylbenzenesulfonamide
(E)-4-(2-(6-bromobenzo[d]thiazol-2-yl)vinyl)-N,N-diethylbenzenesulfonamide
(E)-4-(2-(benzo[d]thiazol-2-yl)vinyl)-2-chloro-N,N-diethylbenzenesulfonamide
(E)-4-(2-(benzo[d]thiazol-2-yl)vinyl)-N,N-diethyl-2-fluorobenzenesulfonamide
(E)-4-(2-(benzo[d]thiazol-2-yl)vinyl)-N,N-diethyl-2-methylbenzenesulfonamide
(E)-4-(2-(benzo[d]thiazol-2-yl)vinyl)-N,N-diethylbenzenesulfonamide
(E)-4-(2-(benzo[d]thiazol-2-yl)vinyl)-N,N-dimethylbenzenesulfonamide
(E)-4-(2-(benzo[d]thiazol-2-yl)vinyl)-N-(4-methoxyphenyl)benzenesulfonamide
(E)-4-(2-(benzo[d]thiazol-2-yl)vinyl)-N-(4-methylbenzyl)benzenesulfonamide
(E)-4-(2-(benzo[d]thiazol-2-yl)vinyl)-N-benzylbenzenesulfonamide
(E)-4-(2-(benzo[d]thiazol-2-yl)vinyl)-N-phenylbenzenesulfonamide
(E)-N,N-diethyl-4-(2-(5-fluorobenzo[d]thiazol-2-yl)vinyl)benzenesulfonamide
(E)-N,N-diethyl-4-(2-(5-methoxybenzo[d]thiazol-2-yl)vinyl)benzenesulfonamide
(E)-N,N-diethyl-4-(2-(5-methylbenzo[d]thiazol-2-yl)vinyl)benzenesulfonamide
(NH4)2SO4
-
competitive against both acetyl-CoA and histones
1,1'-(1,4-phenylene)bis[3-(butylsulfanyl)pyrrolidine-2,5-dione]
-
-
1,3-dibenzyl-5-[(4-hydroxy-2,6-dimethylphenyl)methylidene]-1,3-diazinane-2,4,6-trione
-
-
1,3-dibenzyl-5-[(4-hydroxyphenyl)methylidene]-1,3-diazinane-2,4,6-trione
-
-
1,7-bis(3-bromo-4-hydroxyphenyl)-1,6-heptadiene-3,5-dione
-
-
1-(2-pentylphenyl)ethan-1-ol
-
-
1-(2-pentylphenyl)ethan-1-one
-
-
1-(4-(3-nitrophenyl)thiazol-2-yl)-2-(propan-2-ylidene)hydrazine
-
1-(4-(4-chlorophenyl)thiazol-2-yl)-2-(propan-2-ylidene)hydrazine
1-(S-coenzyme A)hex-5-ene
-
-
1-(S-coenzyme A)propan-2-one
-
-
1-benzyl-3,5-bis[(E)-3-bromo-4-hydroxybenzylidene]piperidin-4-one
81.6% residual activity at 0.1 mM
10-(benzyloxy)-2,3,11-trimethoxy-6,7-dihydro-5H-isoquinolino[3,2-a][2]benzazepin-8-ium chloride
-
-
13,14 disulfoxyisogarcinol
-
LTK-19
14-isopropoxyisogarcinol
-
LTK-13
14-methoxyisogarcinol
-
LTK-14
2'-chloro-N'-(phenylsulfonyl)biphenyl-3-carbohydrazide
-
2'-fluoro-N'-(phenylsulfonyl)biphenyl-3-carbohydrazide
-
2'-methoxy-N'-(phenylsulfonyl)biphenyl-3-carbohydrazide
-
2,2-dimethyl-5-tetradecyl-1,3-dioxane-4,6-dione
-
-
2,2-dimethyl-5-tetradecylidene-1,3-dioxane-4,6-dione
-
-
2,3,11,12-tetramethoxy-6,7-dihydro-5H-isoquinolino[3,2-a][2]benzazepin-8-ium methanesulfonate
-
-
2,3,11-trimethoxy-10-[(4-nitrophenyl)methoxy]-6,7-dihydro-5H-isoquinolino[3,2-a][2]benzazepin-8-ium bromide
-
-
2,3-difluoro-N'-(2-fluorobenzene-1-sulfonyl)-5-(pyridin-2-yl)benzohydrazide
-
WM-1119
2,3-difluoro-N'-(3-methyl-5-(1H-pyrazol-1-yl)benzoyl)benzenesulfonohydrazide
-
2,4-difluoro-N'-(3-methyl-5-(1H-pyrazol-1-yl)benzoyl)benzenesulfonohydrazide
-
2,5-bis[(E)-3-bromo-4-hydroxybenzylidene]cyclopentan-1-one
41.2% residual activity at 0.1 mM
2,5-dihydroxy-3-undecylcyclohexa-2,5-diene-1,4-dione
-
2,5-diphenylisothiazol-3(2H)-one
-
-
2,6-bis(3,4-dibromobenzylidene)cyclohexan-1-one
85.1% residual activity at 0.1 mM
2,6-bis(3-bromo-4-hydroxybenzylidene)cyclohexanone
2,6-bis(3-chloro-4-hydroxybenzylidene)cyclohexan-1-one
7.7% residual activity at 0.1 mM
2,6-bis(3-chloro-5-fluoro-4-hydroxybenzylidene)cyclohexan-1-one
41.1% residual activity at 0.1 mM
2,6-bis(4-hydroxy-3-iodobenzylidene)cyclohexan-1-one
5.8% residual activity at 0.1 mM
2,6-bis[(6-hydroxy-1,1'-biphenyl-3-yl)methylene]cyclohexan-1-one
92.2% residual activity at 0.1 mM
2,6-difluoro-N'-(3-methyl-5-(1H-pyrazol-1-yl)benzoyl)benzenesulfonohydrazide
-
2-(1,3-benzothiazol-2-yl)-1,2-benzothiazol-3(2H)-one
-
-
2-(2-cyclopentylidenehydrazinyl)-4-(3-methoxyphenyl)-1,3-thiazole
-
2-(2-cyclopentylidenehydrazinyl)-4-(3-nitrophenyl)-1,3-thiazole
-
2-(2-cyclopentylidenehydrazinyl)-4-(4-fluorophenyl)-1,3-thiazole
2-(2-cyclopentylidenehydrazinyl)-4-(4-methoxyphenyl)-1,3-thiazole
-
2-(2-cyclopentylidenehydrazinyl)-4-phenyl-1,3-thiazole
-
2-(2-pyridyl)-isothiazol-3(2H)-one
-
-
2-(2-[[(1S)-3-(5-[[5-(3-carbamimidamidopropyl)-3,6-dioxopiperazin-2-yl]methyl]-2-hydroxyphenoxy)-1-carboxypropyl]amino]-2-oxoethyl)-2-hydroxybutanedioic acid
-
NK13650B
2-(3,5-difluoro-4-hydroxyphenyl)-4-((5-(4,5-dimethyl-2-(trifluoromethyl)phenyl)furan-2-yl)methylene)-5-methyl-2,4-dihydro-3H-pyrazol-3-one
-
2-(3,5-difluoro-4-hydroxyphenyl)-4-((5-(4,5-dimethyl-2-nitrophenyl)furan-2-yl)methylene)-5-methyl-2,4-dihydro-3H-pyrazol-3-one
-
2-(3,5-difluoro-4-hydroxyphenyl)-5-methyl-4-((5-(2-(trifluoromethoxy)phenyl)furan-2-yl)methylene)-2,4-dihydro-3H-pyrazol-3-one
-
2-(3,5-difluoro-4-hydroxyphenyl)-5-methyl-4-((5-(3-oxo-2,3-dihydro-1H-inden-4-yl)furan-2-yl)methylene)-2,4-dihydro-3H-pyrazol-3-one
-
2-(3-chloro-4-fluorophenyl)isothiazol-3(2H)-one
-
2-(3-fluoro-5-(2-((2-fluorophenyl)sulfonyl)hydrazinecarbonyl)-phenyl)pyridine 1-Oxide
-
2-(3-methoxyphenyl)isothiazolo[5,4-b]pyridin-3(2H)-one
-
antiproliferative effects in cancer cells, GI50 value 0.007 mM with SK-N-SH cell
2-(3-oxo-1,2-benzothiazol-2(3H)-yl)-N-(1,3-thiazol-2-yl)acetamide
-
-
2-(3-pyridyl)-isothiazol-3(2H)-one
-
-
2-(4,6-dimethyl-3-oxo[1,2]thiazolo[5,4-b]pyridin-2(3H)-yl)ethyl ethylcarbamate
-
-
2-(4-(2H-tetrazol-5-yl) phenyl)-4-((5-(4,5-dimethyl-2-nitrophenyl)furan-2-yl)methylene)-5-methyl-2,4-dihydro-3H-pyrazol-3-one
-
2-(4-(2H-tetrazol-5-yl)phenyl)-4-((5-(4,5-dimethyl-2-nitrophenyl)furan-2-yl)methylene)-5-methyl-2,4-dihydro-3H-pyrazol-3-one
-
2-(4-(trifluoromethyl)benzyl)isothiazolo[5,4-b]pyridin-3(2H)-one
-
antiproliferative effects in cancer cells, GI50 value 0.0005 mM with SK-N-SH cell, 0.030 mM with MCF-7 cell
2-(4-bromophenyl)-5-nitro[1,2]thiazolo[5,4-b]pyridin-3(2H)-one
-
2-(4-dimethylaminoaniline)-isothiazol-3(2H)-one
-
-
2-(4-fluorophenyl)isothiazolo[5,4-b]pyridin-3(2H)-one
-
antiproliferative effects in cancer cells, GI50 value 0.010 mM with SK-N-SH cell, 0.037 mM with MCF-7 cell
2-(4-fluorophenyl)[1,2]thiazolo[5,4-b]pyridin-3(2H)-one
-
PU139
2-(4-methylphenyl)isothiazolo[5,4-b]pyridin-3(2H)-one
-
antiproliferative effects in cancer cells, GI50 value 0.006 mM with SK-N-SH cell
2-(4-morpholinoaniline)-isothiazol-3(2H)-one
-
-
2-(4-pyridyl)-isothiazol-3(2H)-one
-
-
2-(4-[2-[3-(4-chlorophenyl)-5-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazol-1-yl]-1,3-thiazol-4-yl]phenyl)-1H-isoindole-1,3(2H)-dione
-
-
2-(4-[2-[5-(3,4-dimethoxyphenyl)-3-(thiophen-2-yl)-4,5-dihydro-1H-pyrazol-1-yl]-1,3-thiazol-4-yl]phenyl)-1H-isoindole-1,3(2H)-dione
-
-
2-(4-[2-[5-(furan-2-yl)-3-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-1-yl]-1,3-thiazol-4-yl]phenyl)-1H-isoindole-1,3(2H)-dione
-
-
2-(6,7-dihydroxynaphthyl) beta-D-xylopyranoside
-
less than 50% residual activity at 0.1 mM
2-(6,7-dimethoxynaphthyl) beta-D-xylopyranoside
-
about 80% residual activity at 0.1 mM
2-(6-fluoro-3-oxo-1,2-benzothiazol-2(3H)-yl)-N-(4-phenyl-1,3-thiazol-2-yl)acetamide
-
-
2-(6-hydroxy-7-methoxy-naphthyl) beta-D-xylopyranoside
-
less than 50% residual activity at 0.1 mM
2-(7-hydroxy-6-methoxy-naphthyl) beta-D-xylopyranoside
-
about 55% residual activity at 0.1 mM
2-(dimethylamino)-6-pentadecylpyrimidin-4(3H)-one
-
-
2-(dimethylamino)-6-tetradecylpyrimidin-4(3H)-one
-
-
2-(dimethylamino)-6-tridecylpyrimidin-4(3H)-one
-
-
2-(heptylsulfanyl)-1-(2-hydroxyphenyl)ethan-1-one
-
2-(hexylsulfanyl)-1-(2-hydroxyphenyl)ethan-1-one
-
-
2-(methylsulfanyl)-6-tridecylpyrimidin-4(3H)-one
-
-
2-(phenyl)-isothiazolo[5,4-b]pyridin-3(2H)-one
-
-
2-(S-coenzyme A)acetaldehyde
-
-
2-(S-coenzyme A)acetic acid
-
-
2-(S-coenzyme A)acetic acid thiophenyl ester
-
-
2-butyl-6-hydroxybenzoic acid
2-chloro-4-[5-[(E)-[3-[2-(4-methylanilino)-2-oxoethyl]-2,4-dioxo-1,3-thiazolidin-5-ylidene]methyl]furan-2-yl]benzoic acid
-
C375
2-chloro-N'-(naphthalen-2-ylsulfonyl)benzohydrazide
-
2-cyano-N'-(2-fluorobenzoyl)benzenesulfonohydrazide
-
2-decyl-4-hydroxyquinoline-3-carboxylic acid
-
-
2-decyl-6-hydroxybenzoic acid
88% inhibition at 0.05 mM
2-dodecylmalonate
-
compound induces hyperacetylation of specific lysine residues of histone H3, in particular residues K9 and K18, and raises the level of pan-acetylated H4. Compound inhibits the acetylation of all the other H3 and H4 lysines, with the exception of residue K8Ac of histone H4
2-ethylisothiazol-3(2H)-one
-
2-fluoro-3-hydroxy-N'-(3-methyl-5-(1H-pyrazol-1-yl)benzoyl)benzenesulfonohydrazide
-
2-fluoro-3-methyl-N'-(3-methyl-5-(1H-pyrazol-1-yl)benzoyl)benzenesulfonohydrazide
-
2-fluoro-4-methyl-N'-(3-methyl-5-(1H-pyrazol-1-yl)benzoyl)benzenesulfonohydrazide
-
2-fluoro-5-hydroxy-N'-(3-methyl-5-(1H-pyrazol-1-yl)benzoyl)benzenesulfonohydrazide
-
2-fluoro-5-methoxy-N'-(3-methyl-5-(1H-pyrazol-1-yl)benzoyl)benzenesulfonohydrazide
-
2-fluoro-5-methyl-N'-(3-methyl-5-(1H-pyrazol-1-yl)benzoyl)benzenesulfonohydrazide
-
2-fluoro-6-methoxy-N'-(3-methyl-5-(1H-pyrazol-1-yl)benzoyl)benzenesulfonohydrazide
-
2-fluoro-N'-(2-fluoro-5-methyl-3-(1H-pyrazol-1-yl)benzoyl)benzenesulfonohydrazide
-
2-fluoro-N'-(2-fluoro-5-methyl-3-(pyridin-2-yl)benzoyl)benzenesulfonohydrazide
-
2-fluoro-N'-(2-phenylisonicotinoyl)benzenesulfonohydrazide
-
2-fluoro-N'-(3-(3-methyl-1H-pyrazol-1-yl)benzoyl)benzenesulfonohydrazide
-
2-fluoro-N'-(3-(4-fluoro-1H-pyrazol-1-yl)-5-methylbenzoyl)benzenesulfonohydrazide
-
2-fluoro-N'-(3-(4-fluoro-1H-pyrazol-1-yl)benzoyl)benzenesulfonohydrazide
-
2-fluoro-N'-(3-(4-methyl-1H-pyrazol-1-yl)benzoyl)benzenesulfonohydrazide
-
2-fluoro-N'-(3-(furan-2-yl)benzoyl)benzenesulfonohydrazide
-
2-fluoro-N'-(3-(pyridin-2-yl)benzoyl)benzenesulfonohydrazide
-
2-fluoro-N'-(3-(thiophen-2-yl)benzoyl)benzenesulfonohydrazide
-
2-fluoro-N'-(3-(thiophen-3-yl)benzoyl)benzenesulfonohydrazide
-
2-fluoro-N'-(3-fluoro-5-(1H-pyrazol-1-yl)benzoyl)-3-methoxybenzenesulfonohydrazide
-
2-fluoro-N'-(3-fluoro-5-(1H-pyrazol-1-yl)benzoyl)-4-methoxybenzenesulfonohydrazide
-
2-fluoro-N'-(3-fluoro-5-(1H-pyrazol-1-yl)benzoyl)-5-hydroxybenzenesulfonohydrazide
-
2-fluoro-N'-(3-fluoro-5-(1H-pyrazol-1-yl)benzoyl)-5-methoxybenzenesulfonohydrazide
-
2-fluoro-N'-(3-fluoro-5-(2H-1,2,3-triazol-2-yl)benzoyl)benzenesulfonohydrazide
-
2-fluoro-N'-(3-fluoro-5-(3-methyl-1H-pyrazol-1-yl)benzoyl)benzenesulfonohydrazide
-
2-fluoro-N'-(3-fluoro-5-(4-methyl-1H-pyrazol-1-yl)benzoyl)benzenesulfonohydrazide
-
2-fluoro-N'-(3-fluoro-5-(5-methyl-1H-pyrazol-1-yl)benzoyl)benzenesulfonohydrazide
-
2-fluoro-N'-(3-fluoro-5-(pyridin-2-yl)benzoyl)-3-hydroxybenzenesulfonohydrazide
-
2-fluoro-N'-(3-fluoro-5-(pyridin-2-yl)benzoyl)benzenesulfonohydrazide
competes with Ac-CoA by binding to the Ac-CoA binding site
2-fluoro-N'-(3-iodobenzoyl)benzenesulfonohydrazide
-
2-fluoro-N'-(3-isobutoxybenzoyl)benzenesulfonohydrazide
-
2-fluoro-N'-(3-isopropoxybenzoyl)benzenesulfonohydrazide
-
2-fluoro-N'-(3-isopropylbenzoyl)benzenesulfonohydrazide
-
2-fluoro-N'-(3-methoxy-5-(1H-pyrazol-1-yl)benzoyl)-benzenesulfonohydrazide
-
2-fluoro-N'-(3-methoxy-5-(1H-pyrazol-1-yl)benzoyl)benzenesulfonohydrazide
-
2-fluoro-N'-(3-methoxy-5-(3-methyl-1H-pyrazol-1-yl)benzoyl)benzenesulfonohydrazide
-
2-fluoro-N'-(3-methoxy-5-(pyrimidin-2-yl)benzoyl)-benzenesulfonohydrazide
-
2-fluoro-N'-(3-methyl-5-(1H-pyrazol-1-yl)benzoyl)benzenesulfonohydrazide
-
2-fluoro-N'-(3-methyl-5-(2H-1,2,3-triazol-2-yl)benzoyl)benzenesulfonohydrazide
-
2-fluoro-N'-(3-methyl-5-(3-methyl-1H-pyrazol-1-yl)benzoyl)benzenesulfonohydrazide
-
2-fluoro-N'-(3-methyl-5-(4-methyl-1H-pyrazol-1-yl)benzoyl)benzenesulfonohydrazide
-
2-fluoro-N'-(3-methyl-5-(5-methyl-1H-pyrazol-1-yl)benzoyl)benzenesulfonohydrazide
-
2-fluoro-N'-(3-methylbenzoyl)benzenesulfonohydrazide
-
2-fluoro-N'-(3-propoxybenzoyl)benzenesulfonohydrazide
-
2-fluoro-N'-(3-propylbenzoyl)benzenesulfonohydrazide
-
2-fluoro-N'-(4-fluoro-5-methyl-[1,1'-biphenyl]-3-carbonyl)benzenesulfonohydrazide
-
2-fluoro-N'-(5-fluoro-[1,1'-biphenyl]-3-carbonyl)-3-hydroxybenzenesulfonohydrazide
-
2-fluoro-N'-(5-fluoro-[1,1'-biphenyl]-3-carbonyl)-4-hydroxybenzenesulfonohydrazide
-
2-fluoro-N'-(5-fluoro-[1,1'-biphenyl]-3-carbonyl)-4-methoxybenzenesulfonohydrazide
-
2-fluoro-N'-(5-phenylnicotinoyl)benzenesulfonohydrazide
-
2-fluoro-N'-(6-phenylpicolinoyl)benzenesulfonohydrazide
-
2-fluoro-N'-(naphthalene-2-sulfonyl)benzohydrazide
2-fluoro-N'-(phenylsulfonyl)benzohydrazide
-
2-fluoro-N'-[(3-fluorophenyl)sulfonyl]benzohydrazide
-
2-fluoro-N'-[[3-(trifluoromethyl)phenyl]sulfonyl]benzohydrazide
-
2-hydroxy-5-nonylbenzoic acid
-
-
2-hydroxy-5-pentadecylbenzoic acid
85% inhibition at 0.05 mM
2-hydroxy-5-pentylbenzoic acid
-
2-hydroxy-5-tetradecylbenzoic acid
-
-
2-hydroxy-6-(11-hydroxyundecyl)benzoic acid
2-hydroxy-6-(5-hydroxypentyl)benzoic acid
-
2-hydroxy-6-nonylbenzoic acid
-
-
2-hydroxy-6-pentadecylbenzoic acid
2-hydroxy-6-tetradecylbenzoic acid
-
-
2-hydroxy-6-[(8E,11E)-pentadeca-8,11,14-trienyl]benzoic acid
-
2-hydroxy-6-[(E)-pentadec-8-enyl]benzoic acid
-
2-hydroxy-6-[(Z)-2-[4-(pentyloxy)phenyl]ethenyl]benzoic acid
-
-
2-hydroxy-N'-(naphthalen-2-ylsulfonyl)benzohydrazide
-
2-pentylisothiazol-3(2H)-one
-
2-phenyl-5-(trityloxymethyl)isothiazol-3(2H)-one
-
-
2-phenylisothiazol-3(2H)-one
-
-
2-sulfanylidene-6-tridecyl-2,3-dihydropyrimidin-4(1H)-one
-
-
2-tert-butyl-5-(dodecylthio)isothiazol-3(2H)-one-1-oxide
-
-
2-tert-butyl-5-chloroisothiazol-3(2H)-one 1-oxide
-
-
2-tridecylmalonate
-
inhibition of the acetylation of histone H3 residuesK9/K18, being practically inactive in all the other assays
2-undecylmalonate
-
compound exhibits a significant inhibition of the acetylation of almost any lysine residue explored, with the sole exception of residue K8 of H4. Compound reduces the level of K5Ac of H4 and, more markedly, K16Ac of H4
2-[(1E)-1-[2-[4-(4-chlorophenyl)-1,3-thiazol-2-yl]hydrazinylidene]ethyl]pyridine
-
2-[(1Z)-1-[(3E)-3-[2-[4-(4-chlorophenyl)-1,3-thiazol-2-yl]hydrazinylidene]cyclopentylidene]ethyl]pyridine
-
-
2-[(3,4-dichlorophenyl)methyl]-1H-1l4-[1,2]thiazolo[5,4-b]pyridine-1,3(2H)-dione
-
-
2-[(3,4-dichlorophenyl)methyl]-1H-1l6-[1,2]thiazolo[5,4-b]pyridine-1,1,3(2H)-trione
-
-
2-[(4-bromophenyl)methyl]-5-methyl[1,2]thiazolo[5,4-b]pyridin-3(2H)-one
-
NSC694614
2-[(4-methoxyphenyl)methyl]-5-nitro[1,2]thiazolo[5,4-b]pyridin-3(2H)-one
-
NSC694622
2-[2-(4-heptylphenyl)ethyl]-6-hydroxybenzoic acid
2-[4-(4-methylphenyl)-1,3-thiazol-2-yl]-1,2-benzothiazol-3(2H)-one
-
-
2-[[4-(trifluoromethyl)phenyl]methyl][1,2]thiazolo[5,4-b]pyridin-3(2H)-one
-
PU141
3'-chloro-N'-(phenylsulfonyl)biphenyl-3-carbohydrazide
-
3'-cyano-N'-(phenylsulfonyl)biphenyl-3-carbohydrazide
-
3'-fluoro-N'-(phenylsulfonyl)biphenyl-3-carbohydrazide
-
3'-methoxy-N'-(phenylsulfonyl)biphenyl-3-carbohydrazide
-
3'-O-(4-benzoylbenzoyl)adenosine 5'-triphosphate
ZINC65731330
3,3'-[(2-oxocyclohexane-1,3-diylidene)di(E)methanylylidene]dibenzonitrile
-
-
3-(2-(2-fluorobenzoyl)hydrazinylsulfono)benzamide
-
3-(Z)-(benzylsulfanyl)propenoic acid
-
-
3-(Z)-(benzylsulfinyl)-2-N-(4-dimethylaminoanilino)-propenamide
-
-
3-(Z)-(benzylsulfinyl)-2-N-(4-morpholinoanilino)-propenamide
-
-
3-(Z)-(benzylsulfinyl)-N-(2-pyridyl)propenamide
-
-
3-(Z)-(benzylsulfinyl)-N-(3-pyridyl)propenamide
-
-
3-(Z)-(benzylsulfinyl)-N-(4-pyridyl)propenamide
-
-
3-amino-N'-(2-fluorobenzoyl)benzenesulfonohydrazide
-
3-bromo-N'-(3-ethoxybenzoyl)-2-fluorobenzenesulfonohydrazide
-
3-chloro-N'-(2-fluorobenzoyl)benzenesulfonohydrazide
-
3-chloro-N'-(naphthalen-2-ylsulfonyl)benzohydrazide
-
3-cyano-N'-(2-fluorobenzoyl)benzenesulfonohydrazide
-
3-fluoro-N'-(2-fluorobenzene-1-sulfonyl)-5-(1H-pyrazol-1-yl)benzohydrazide
-
3-fluoro-N'-(2-fluorobenzene-1-sulfonyl)-5-(furan-2-yl)benzohydrazide
-
3-fluoro-N'-(2-fluorobenzene-1-sulfonyl)-5-(pyrimidin-2-yl)benzohydrazide
-
3-fluoro-N'-(2-fluorobenzoyl)benzenesulfonohydrazide
-
3-methyl-N'-(naphthalen-2-ylsulfonyl)benzohydrazide
-
3-pentadecylidenepentane-2,4-dione
-
inhibition of the acetylation of histone H3 residuesK9/K14, being practically inactive in all the other assays
3-quinolinecarboxylic acid ethyl ester
3-Z-benzylsulfanyl-4-trityloxy-but-2-enoic acid phenylamide
-
-
3-Z-benzylsulfinyl-4-trityloxy-but-2-enoic acid phenylamide
-
-
3-[(1E)-1-[2-[4-(4-chlorophenyl)-1,3-thiazol-2-yl]hydrazinylidene]ethyl]-2H-1-benzopyran-2-one
-
3-[(1Z)-1-[(3E)-3-[2-[4-(4-chlorophenyl)-1,3-thiazol-2-yl]hydrazinylidene]cyclopentylidene]ethyl]-2H-1-benzopyran-2-one
-
-
3-[(E)-[2-[4-(4-chlorophenyl)-1,3-thiazol-2-yl]hydrazinylidene]methyl]-2,3-dihydro-1H-indole
-
3-[(Z)-[(3E)-3-[2-[4-(4-chlorophenyl)-1,3-thiazol-2-yl]hydrazinylidene]cyclopentylidene]methyl]-1H-indole
-
-
3-[2-(pentadecanoylamino)benzamido]benzoic acid
-
-
3-[2-(tridecanoylamino)benzamido]benzoic acid
-
-
3-[2-[(2E)-2-(3-methylcyclopentylidene)hydrazinyl]-1,3-thiazol-4-yl]-2H-1-benzopyran-2-one
-
-
3-[2-[(2Z)-2-(3-methylcyclopentylidene)hydrazinyl]-1,3-thiazol-4-yl]-2H-1-benzopyran-2-one
-
3-[2-[2-(propan-2-ylidene)hydrazinyl]-1,3-thiazol-4-yl]-2H-1-benzopyran-2-one
-
4'-chloro-N'-(phenylsulfonyl)biphenyl-3-carbohydrazide
-
4'-cyano-N'-(phenylsulfonyl)biphenyl-3-carbohydrazide
-
4'-fluoro-N'-(phenylsulfonyl)biphenyl-3-carbohydrazide
-
4'-methoxy-N'-(phenylsulfonyl)biphenyl-3-carbohydrazide
-
4,4'-(2-hydroxycyclohexane-1,3-diylidene)bis(methanylylidene)-bis(2-bromophenol)
12.5% residual activity at 0.1 mM
4,5-dichloro-2-ethylisothiazol-3(2H)-one
-
-
4,5-dichloro-2-ethylisothiazol-3(2H)-one-1-oxide
-
-
4-((5-(4,5-dimethyl-2-nitrophenyl)furan-2-yl)methylene)-5-methyl-2-(4- (methylsulfonyl) phenyl)-2,4-dihydro-3H-pyrazol-3-one
-
4-((5-(4,5-dimethyl-2-nitrophenyl)furan-2-yl)methylene)-5-methyl-2-(4-(methylsulfonyl)phenyl)-2,4-dihydro-3H-pyrazol-3-one
-
4-(3-cyclopropyl-4-((5-(4,5-dimethyl-2-(trifluoromethyl)phenyl)thiophen- 2-yl)methylene)-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)benzoic acid
-
4-(3-cyclopropyl-4-((5-(4,5-dimethyl-2-nitrophenyl)furan-2-yl)methylene)-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)benzoic acid
-
4-(3-methyl-4-((5-(2-nitrophenyl)furan-2-yl)methylene)-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)benzoic acid
-
4-(3-methyl-5-oxo-4-((5-(2-(trifluoromethoxy)phenyl)furan-2-yl)methylene)-4,5-dihydro-1H-pyrazol-1-yl)benzoic acid
-
4-(3-methyl-5-oxo-4-((5-(3-oxo-2,3-dihydro-1H-inden-4-yl)furan-2-yl)methylene)-4,5-dihydro-1H-pyrazol-1-yl)benzoic acid
-
4-(3-oxo-1,2-benzothiazol-2(3H)-yl)butanoic acid
-
-
4-(4-((2-(4,5-dimethyl-2-nitrophenyl)thiazol-5-yl)methylene)-3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)benzoic acid
-
4-(4-((5-(2-(difluoromethyl)phenyl)furan-2-yl)methylene)-3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)benzoic acid
-
4-(4-((5-(2-(dimethylphosphoryl)phenyl)furan-2-yl)methylene)-3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)benzoic acid
-
4-(4-((5-(4,5-dimethyl-2-(trifluoromethyl)phenyl)furan-2-yl)methylene)-3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)benzoic acid
-
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-1H-pyrrol-2-yl)methylene)-3-methyl-5-oxo-4, 5-dihydro-1H-pyrazol-1-yl)benzoic acid
-
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)furan-2-yl)methylene)-2,5-dioxoimidazolidin-1-yl)benzoic acid
-
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)furan-2-yl)methylene)-3-ethyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)benzoic acid
-
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)furan-2-yl)methylene)-3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)benzoic acid
C646, selective inhibitor
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)furan-2-yl)methylene)-3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)benzonitrile
-
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)thiophen-2-yl)methylene)-3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)benzoic acid
-
4-(4-(1-(5-(4,5-dimethyl-2-nitrophenyl)furan-2-yl)ethylidene)-3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)benzoic acid
-
4-(4-(2-((4,5-dimethyl-2-nitrophenyl)amino)-2-oxoethyl)-3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)benzoic acid
-
4-(4-(3-((4,5-dimethyl-2-nitrophenyl)amino)-3-oxopropyl)-3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)benzoic acid
-
4-(4-bromophenyl)-2-[2-(propan-2-ylidene)hydrazinyl]-1,3-thiazole
4-(4-chlorophenyl)-2-(2-cyclopentylidenehydrazinyl)-1,3-thiazole
4-(4-chlorophenyl)-2-[(2E)-2-(3-cyclooctylcyclopentylidene)hydrazinyl]-1,3-thiazole
-
-
4-(4-chlorophenyl)-2-[(2E)-2-(3-methylcyclopentylidene)hydrazinyl]-1,3-thiazole
-
CPTH6
4-(4-chlorophenyl)-2-[(2E)-2-[(3Z)-3-(1-cyclohexylethylidene)cyclopentylidene]hydrazinyl]-1,3-thiazole
-
-
4-(4-chlorophenyl)-2-[(2E)-2-[(3Z)-3-(4,4-dimethylcyclohex-2-en-1-ylidene)cyclopentylidene]hydrazinyl]-1,3-thiazole
-
-
4-(4-chlorophenyl)-2-[(2E)-2-[(3Z)-3-[1-(1,3-thiazol-2-yl)ethylidene]cyclopentylidene]hydrazinyl]-1,3-thiazole
-
-
4-(4-chlorophenyl)-2-[(2E)-2-[1-(1,3-thiazol-2-yl)ethylidene]hydrazinyl]-1,3-thiazole
-
4-(4-chlorophenyl)-2-[(2E)-2-[3-(propan-2-ylidene)cyclopentylidene]hydrazinyl]-1,3-thiazole
-
-
4-(4-chlorophenyl)-2-[2-(propan-2-ylidene)hydrazinyl]-1,3-thiazole
-
4-(4-nitrophenyl)-2-[2-(propan-2-ylidene)hydrazinyl]-1,3-thiazole
-
-
4-(5-((5-(4,5-dimethyl-2-nitrophenyl)furan-2-yl)methylene)-2,4- dioxothiazolidin-3-yl)benzoic acid
-
4-(5-(4,5-dimethyl-2-nitrobenzoyl)-1H-indazol-1-yl)benzoic acid
-
4-(5-(4,5-dimethyl-2-nitrobenzoyl)-1H-indol-1-yl)benzoic acid
-
4-(5-(4,5-dimethyl-2-nitrobenzyl)-1H-indazol-1-yl)benzoic acid
-
4-(aminoacetyl)-N-benzyl-2-methyl-3,4-dihydro-2H-1,4-benzothiazine-7-sulfonamide
-
-
4-([(2E)-2-cyano-3-[5-(4,5-dimethyl-2-nitrophenyl)furan-2-yl]prop-2-enoyl]amino)benzoic acid
-
4-([4-[3-(methoxycarbonyl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-hexahydroquinolin-4-yl]phenoxy]methyl)benzoic acid
-
-
4-acetyl-2-methyl-3,4-dihydro-2H-1,4-benzothiazine-7-sulfonamide
-
-
4-acetyl-2-methyl-N-(morpholin-4-yl)-3,4-dihydro-2H-1,4-benzothiazine-7-sulfonamide
4-acetyl-2-methyl-N-phenyl-3,4-dihydro-2H-1,4-benzothiazine-7-sulfonamide
-
-
4-acetyl-2-methyl-N-propyl-3,4-dihydro-2H-1,4-benzothiazine-7-sulfonamide
-
-
4-acetyl-N,N-dibenzyl-2-methyl-3,4-dihydro-2H-1,4-benzothiazine-7-sulfonamide
-
-
4-acetyl-N-benzyl-2-methyl-3,4-dihydro-2H-1,4-benzothiazine-7-sulfonamide
-
-
4-acetyl-N-cyclohexyl-2-methyl-3,4-dihydro-2H-1,4-benzothiazine-7-sulfonamide
-
-
4-acetyl-N-[(3-bromophenyl)methyl]-2-methyl-3,4-dihydro-2H-1,4-benzothiazine-7-sulfonamide
-
-
4-acetyl-N-[(4-methoxyphenyl)methyl]-2-methyl-3,4-dihydro-2H-1,4-benzothiazine-7-sulfonamide
-
-
4-amino-N'-(2-fluorobenzoyl)benzenesulfonohydrazide
-
4-azidomethyl-2-phenyl-isothiazol-3(2H)-one
-
-
4-bromomethyl-2-phenylisothiazol-3(2H)-one
-
-
4-butoxy-N'-(naphthalen-2-ylsulfonyl)benzohydrazide
-
4-chloro-N'-(naphthalen-2-ylsulfonyl)benzohydrazide
-
4-cyano-N'-(2-fluorobenzoyl)benzenesulfonohydrazide
-
4-hydroxy-2-methylquinoline-3-carboxylic acid
-
-
4-hydroxy-2-pentadecylquinoline-3-carboxylic acid
-
-
4-hydroxy-2-pentylquinoline-3-carboxylate
-
effects in vivo, overview, in vitro clear reduction of the acetylation extents of both histone H3 and alpha-tubulin at 0.1 mM
4-hydroxy-2-pentylquinoline-3-carboxylic acid
4-hydroxy-3-[(E)-[[2-(3-iodophenyl)-1,3-benzoxazol-5-yl]imino]methyl]benzoic acid
-
C146
4-hydroxy-N'-(naphthalen-2-ylsulfonyl)benzohydrazide
-
4-methoxymethyl-2-phenyl-isothiazol-3(2H)-one
-
-
4-methyl-2-phenylisothiazol-3(2H)-one
-
-
4-methyl-5-methoxy-2-phenyl-isothiazol-3(2H)-one
-
-
4-trityloxy-but-2-ynoic acid phenylamide
-
-
4-[(4Z)-4-[[5-(4,5-dimethyl-2-nitrophenyl)furan-2-yl]methylidene]-3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl]-N-(prop-2-yn-1-yl)benzamide
i.e. C646-yne, docking study and protein interaction analysis, formation of a stable C646-cysteine adducts. The major targets of C646-yne reactivity are abundant cellular proteins containing reactive cysteine residues
4-[(4Z)-4-[[5-(4,5-dimethyl-2-nitrophenyl)furan-2-yl]methylidene]-3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl]benzoic acid
i.e. C646, inhibits the lysine acetyltransferases (KATs) p300 and CBP and represents a very potent and selective small molecule KAT inhibitor, docking study and protein interaction analysis. The pyrazolone-furan of C646 is an electrophilic chemotype capable of irreversible protein reactivity
4-[2-(pentadecanoylamino)benzamido]benzoic acid
-
-
4-[2-(tridecanoylamino)benzamido]benzoic acid
-
-
4-[4-(3,4-dicarboxybenzamido)phenoxy]benzene-1,2-dicarboxylic acid
ZINC03143991
4-[4-(3,4-dimethylbenzamido)phenoxy]benzene-1,2-dicarboxylic acid
-
4-[4-(3-methylbenzamido)phenoxy]benzene-1,2-dicarboxylic acid
ZINC09694266
4-[[(4-methoxybenzene-1-sulfonyl)oxy]imino]-2,6-dimethylcyclohexa-2,5-dien-1-one
-
L002
4-[[2,6-dibromo-4-(3,3,6,6-tetramethyl-1,8-dioxo-1,2,3,4,5,6,7,8,9,10-decahydroacridin-9-yl)phenoxy]methyl]benzoic acid
-
DC-G16-11
4-[[2,6-dichloro-4-(1,8-dioxo-1,2,3,4,5,6,7,8,9,10-decahydroacridin-9-yl)phenoxy]methyl]benzoic acid
-
-
4-[[2-bromo-4-(3,3,6,6-tetramethyl-1,8-dioxo-1,2,3,4,5,6,7,8,9,10-decahydroacridin-9-yl)phenoxy]methyl]benzoic acid
-
-
4-[[4-(1,8-dioxo-1,2,3,4,5,6,7,8,9,10-decahydroacridin-9-yl)-2-methoxyphenoxy]methyl]benzoic acid
-
-
4-[[4-(3-cyano-2-methyl-5-oxo-1,4,5,6,7,8-hexahydroquinolin-4-yl)phenoxy]methyl]benzoic acid
-
-
4-[[4-(8-oxo-7,8,9,10,11,12-hexahydrobenzo[c]acridin-7-yl)phenoxy]methyl]benzoic acid
-
-
5,5'-disulfanediylbis(1,2-thiazole)
-
NU9056
5,5'-[(5-carboxy-2-oxocyclohexane-1,3-diylidene)bis(methanylylidene)]bis(2-hydroxybenzoic acid)
70.1% residual activity at 0.1 mM
5-acetoxymethyl-2-phenylisothiazol-3(2H)-one
-
-
5-azidomethyl-2-phenylisothiazol-3(2H)-one
-
-
5-bromo-2-(dimethylamino)-6-tetradecylpyrimidin-4(3H)-one
-
-
5-bromo-2-(dimethylamino)-6-tridecylpyrimidin-4(3H)-one
-
-
5-bromo-N'-(3-ethoxybenzoyl)-2-fluorobenzenesulfonohydrazide
-
5-butyl-2-hydroxybenzoic acid
-
-
5-chloro-2-(3-chloro-4-fluorophenyl)isothiazol-3(2H)-one
-
5-chloro-2-(4-nitrophenyl)-1,2-thiazol-3(2H)-one
-
CCT077791
5-chloro-2-ethyl-4-methyl-1H-1l4,2-thiazole-1,3(2H)-dione
-
-
5-chloro-2-ethyl-4-methylisothiazol-3(2H)-one
-
-
5-chloro-2-ethyl-4-methylisothiazol-3(2H)-one-1-oxide
-
-
5-chloro-2-ethylisothiazol-3(2H)-one
5-chloro-2-ethylisothiazol-3(2H)-one-1-oxide
-
-
5-chloro-2-pentylisothiazol-3(2H)-one
-
5-chloro-4-methyl-2-phenylisothiazol-3(2H)-one
-
-
5-chloro-6-[([1-[(2R)-2-hydroxy-2-(6-methoxyquinolin-4-yl)ethyl]piperidin-4-yl]amino)methyl]-1,3-benzoxazol-2(3H)-one
-
5-decyl-2-hydroxybenzoic acid
95% inhibition at 0.05 mM
5-hydroxy-2,3-dimethylnaphthalene-1,4-dione
-
PTK1
5-hydroxy-2-methylnaphthalene-1,4-dione
-
RTK1
5-hydroxymethyl-2-phenylisothiazol-3(2H)-one
-
-
5-methyl-2-phenylisothiazol-3(2H)-one
-
-
5-phenylureidomethyl-2-phenylisothiazol-3(2H)-one
-
-
6-(4-chlorophenyl)-2-(2-(3-methylcyclopentylidene)hydrazinyl)pyrimidin-4(3H)-one
-
6-(4-chlorophenyl)-2-(2-cyclopentylidenehydrazinyl)pyrimidin-4(3H)-one
-
6-(4-chlorophenyl)-2-[(2E)-2-(3-methylcyclopentylidene)hydrazinyl]pyrimidin-4(3H)-one
-
-
6-dodecyl-2-(methylsulfanyl)pyrimidin-4(3H)-one
-
-
6-dodecyl-2-sulfanylidene-2,3-dihydropyrimidin-4(1H)-one
-
-
6-[(4S)-5-(ethoxycarbonyl)-6-methyl-2-oxo-4-phenyl-3,4-dihydropyrimidin-1(2H)-yl]hexanoic acid
ZINC14246093
6-[(4S)-5-(ethoxycarbonyl)-6-methyl-2-oxo-4-[4-(trifluoromethoxy)phenyl]-3,4-dihydropyrimidin-1(2H)-yl]hexanoic acid
ZINC40152345
6-[(4S)-5-(ethoxycarbonyl)-6-methyl-4-(3-nitrophenyl)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl]hexanoic acid
-
6-[(4S)-5-[(benzyloxy)carbonyl]-4-([1,1'-biphenyl]-4-yl)-6-methyl-2-oxo-3,4-dihydropyrimidin-1(2H)-yl]hexanoic acid
ZINC08829517
8-benzyl-10,11-dimethoxy-5,6,7,9,14,14a-hexahydro-2H-[1,3]dioxolo[4,5-h]isoquinolino[3,2-a][2]benzazepin-8-ium bromide
-
-
8-benzyl-11,12-dimethoxy-5,6,7,9,14,14a-hexahydro-2H-[1,3]dioxolo[4,5-h]isoquinolino[3,2-a][2]benzazepin-8-ium bromide
-
-
8-benzyl-2,3,10,11-tetramethoxy-5,6,7,9-tetrahydroisoquinolino[3,2-a][2]benzazepin-8-ium chloride
-
-
8-benzyl-2,3,11,12-tetramethoxy-5,6,7,9-tetrahydroisoquinolino[3,2-a][2]benzazepin-8-ium bromide
-
-
9-[3-bromo-4-[(3-fluorophenyl)methoxy]phenyl]-3,4,6,7,9,10-hexahydroacridine-1,8(2H,5H)-dione
-
-
9-[4-(benzyloxy)-3-bromophenyl]-3,3,6,6-tetramethyl-3,4,6,7,9,10-hexahydroacridine-1,8(2H,5H)-dione
-
-
A-485
Ac-ARTK(me)QTARK(me)3STGGK(CoA)APRKQL
-
-
Ac-ARTK(me)QTARKSTGGK(Br)APRKQL
-
-
Ac-ARTK(me)QTARKSTGGK(CoA)APRKQL
-
-
Ac-ARTKQTARK(me)3STGGK(Sme)APRKQL
-
-
Ac-ARTKQTARKSTGGK(Br)APRKQL
-
-
Ac-ARTKQTARKSTGGK(CoA)APRKQL
-
-
Ac-L-Lys(CoA)-NH2
bisubstrate inhibitor
acetylated histone H3 peptide
-
allspice hot water extract
-
leads to a potent anti-HAT activity since the allspice hot water extract possesses a strong inhibitory effect on p300 and CBP (40% at 0.1 ng/ml). Chromatin immunoprecipitation indicates that the acetylation of histone H3 in the PSA and B2M promoter regions was also repressed
-
anacardic acid
anarcadic acid
-
B-homo berberine
-
10,11-dimethoxy-6,7-dihydro-2H,5H-[1,3]dioxolo[4,5-h]isoquinolino[3,2-a][2]benzazepin-8-ium methanesulfonate
B-homo palmatine
-
2,3,10,11-tetramethoxy-6,7-dihydro-5H-isoquinolino[3,2-a][2]benzazepin-8-ium methanesulfonate
benzyl [2-(5-chloro-3-oxoisothiazol-2(3H)-yl)ethyl]carbamate
-
bisubstrate analogue histone H3-peptide-coenzyme A
-
bisubstrate analogue methyl-histone H3-peptide-coenzyme A
-
peptide consisting of 20 and 7 amino acid residues
-
Brij-58
catechin
-
-
CCT004463
-
in vivo cell proliferation inhibition
CCT004464
-
in vivo cell proliferation inhibition
CCT004465
-
in vivo cell proliferation inhibition
CCT004466
-
in vivo cell proliferation inhibition
CCT004467
-
in vivo cell proliferation inhibition
CCT077791
-
IC50: 0.0022-0.0073 mM, in vivo cell proliferation inhibition, reduces acetylation of histones H3 and H4 and alpha-tubulin in cancer cell lines
CCT077792
-
IC50: 0.0027-0.015 mM, in vivo cell proliferation inhibition
CCT077796
-
IC50: 0.0187-0.0202 mM, in vivo cell proliferation inhibition
CCT079769
-
IC50: 0.0547 mM, in vivo cell proliferation inhibition
chondroitin sulfate
-
-
CPTH2
CPTH6
27% inhibition at 0.1 mM; 40% inhibition at 0.8 mM; 40% inhibition at 0.8 mM
CTX-0124143
i.e. N'-(2-fluorobenzoyl)naphthalene-2-sulfonohydrazide
Cu2+
-
5 mM, enzyme form B
curcumin
delphinidin
-
-
DELTA12-prostaglandin J2
-
-
desulfo-coenzyme A
diethyl (1-aminotetradecyl)propanedioate
-
-
diethyl (1-chlorotetradecyl)propanedioate
-
-
diethyl (1-hydroxytetradecyl)propanedioate
-
-
diethyl (pentadecan-2-yl)propanedioate
-
-
diethyl 2-tetradecylidenemalonate
-
compound exhibits a significant inhibition of the acetylation of almost any lysine residue explored, with the sole exception of residue K8 of H4. Compound reduces the level of K5Ac of H4 and, more markedly, K16Ac of H4
diethyl benzylidenepropanedioate
-
-
diethyl decylidenepropanedioate
-
-
diethyl dodecylidenepropanedioate
-
-
diethyl dodecylpropanedioate
-
-
diethyl pentadecylidenepropanedioate
i.e. SPV106, a long-chain alkylidenemalonate (LoCAM), 74% inhibition at 0.05 mM
diethyl tetradecylidenepropanedioate
-
-
diethyl tetradecylpropanedioate
-
-
diethyl tridecylidenepropanedioate
-
-
diethyl tridecylpropanedioate
-
-
diethyl undecylidenepropanedioate
-
-
diethyl [(dodecylamino)methylidene]propanedioate
-
-
diethyl [(naphthalen-1-yl)methylidene]propanedioate
-
-
diethyl [(naphthalen-2-yl)methylidene]propanedioate
-
-
dimethyl sulfoxide
-
irreversible at 2% v/v
dithiothreitol
-
10 mM: stimulation, 100 mM: inhibition
epigallocatechin-3-gallate
ethanol
-
irreversible at 2% v/v
ethyl (3E,5E)-3,5-bis[(3-bromo-4-hydroxyphenyl)methylidene]-4-oxocyclohexane-1-carboxylate
-
-
ethyl 2-decyl-4-hydroxyquinoline-3-carboxylate
-
-
ethyl 2-methyl-6-([5-[(prop-2-yn-1-yl)amino]pentyl]oxy)quinoline-3-carboxylate
ethyl 2-methylquinoline-3-carboxylate
ethyl 3-(5-chloro-3-oxoisothiazol-2(3H)-yl)propanoate
-
ethyl 4-hydroxy-2-methylquinoline-3-carboxylate
-
-
ethyl 4-hydroxy-2-pentadecylquinoline-3-carboxylate
-
-
ethyl 4-hydroxy-2-pentylquinoline-3-carboxylate
-
-
ethyl 4-oxo-2-sulfanylidene-6-tetradecyl-1,2,3,4-tetrahydropyrimidine-5-carboxylate
-
-
ethyl quinoline-3-carboxylate
-
MC1752
gamma-butyrolactone
-
MB-3
garcinol
geminin
-
a Cdt1 repressor, inhibits HBO1 acetylase activity in a a Cdt1-dependent manner in the context of a Cdt1-HBO1 complex, and it associates with origins and inhibits H4 acetylation and licensing in vivo, but geminin does not block the interaction of Cdt1 with HBO1 in vitro or Cdt1-dependent recruitment of HBO1 to replication origins in vivo
-
H3-CoA-20
H3-CoA-20-Tat
-
IC50: 0.012 mM, recombinant enzyme
-
HC toxin
cyclic tetrapeptide, decreases enzyme form B expression
heparan sulfate proteoglycans
-
heparan sulfate proteoglycans isolated from corneal and pulmonary fibroblasts inhibit HAT activity with similar effectiveness as heparin
-
heparin
-
ability of heparin to inhibit HAT is dependent upon its size and structure: small heparin-derived oligosaccharides (above 8 sugars) and N-desulfated or O-desulfated heparin show reduced inhibitory activity. Heparin is shown to bind to pCAF. Enzyme assays indicate that heparin shows the characteristics of a competitive-like inhibitor causing a 50fold increase in the Km of pCAF for histone H4
heptylbenzene
-
-
histone
histone H3-peptide mutant K14A
-
dead-end inhibitor analogue, mutant histone H3 -peptide consisting of amino acid residues 3-20 K14A
-
hyaluronic acid
-
-
iodoacetamide
isogarcinol
Isopropanol
-
irreversible at 2% v/v
isothiazole
-
-
isothiazolone
Keratan sulfate
-
-
L-Lys-CoA
-
-
LTK14
Lys-CoA
Lys-CoA-Tat
-
IC50: 250 nM, recombinant enzyme, complete inhibition of acetylation of the promyelotic leukemia zinc finger gene
methyl 2-(5-chloro-3-oxoisothiazol-2(3H)-yl)ethanoate
-
methyl 3-(3-oxoisothiazol-2(3H)-yl)propanoate
-
methyl 3-(4,5-dichloro-1-oxido-3-oxoisothiazol-2(3H)-yl)propanoate
-
-
methyl 3-(4,5-dichloro-3-oxoisothiazol-2(3H)-yl)propanoate
-
-
methyl 3-(5-chloro-1,3-dioxo-1,3-dihydro-2H-1l4,2-thiazol-2-yl)propanoate
-
-
methyl 3-(5-chloro-1-oxido-3-oxoisothiazol-2(3H)-yl)propanoate
methyl 3-(5-chloro-3-oxo-1,2-thiazol-2(3H)-yl)propanoate
-
-
methyl 3-(5-chloro-3-oxoisothiazol-2(3H)-yl)propanoate
-
-
methyl 3-(5-chloro-3-oxoisothiazol-2(3H)-yl)propanoic acid
-
methyl 3-(5-chloro-4-methyl-1,3-dioxo-1,3-dihydro-2H-1l4,2-thiazol-2-yl)propanoate
-
-
methyl 3-(5-chloro-4-methyl-1-oxido-3-oxoisothiazol-2(3H)-yl)propanoate
-
-
methyl 3-(5-chloro-4-methyl-3-oxoisothiazol-2(3H)-yl)propanoate
-
-
methyl 3-[(5-chloro-1,2-thiazol-3-yl)amino]propanoate
-
-
methyl 3-[(5-chloroisothiazol-3-yl)amino]propanoate
-
methyl 3-[4-chloro-5-(dodecylthio)-1-oxido-3-oxoisothiazol-2(3H)-yl]propanoate
-
-
methyl 3-[4-[[(benzyloxy)carbonyl]amino]-5-chloro-3-oxo-1,2-thiazol-2(3H)-yl]propanoate
-
-
methyl 3-[4-{[(benzyloxy)carbonyl]amino}-5-chloro-3-oxoisothiazol-2(3H)-yl]propanoate
-
methyl 3-[5-(dodecylthio)-1-oxido-3-oxoisothiazol-2(3H)-yl] propanoate
-
-
methyl 4-(3-oxoisothiazol-2(3H)-yl)butanoate
-
methyl 4-(5-chloro-3-oxoisothiazol-2(3H)-yl)butanoate
-
methyl 5-(5-chloro-3-oxoisothiazol-2(3H)-yl)pentanoate
-
methyl 6-(5-chloro-3-oxoisothiazol-2(3H)-yl)hexanoate
-
MG149
montelukast
-
decreases HAT activity by attenuating the activating effect of TNF-alpha
N'-( 2-fluoro-[1,1'- biphenyl]-3-carbonyl)-benzenesulfonohydrazide
-
N'-(2,3-difluorobenzoyl)benzenesulfonohydrazide
-
N'-(2,3-difluorobenzoyl)naphthalene-2-sulfonohydrazide
-
N'-(2,6-difluorobenzene-1-sulfonyl)-3-fluoro-5-propoxybenzohydrazide
-
N'-(2,6-difluorobenzene-1-sulfonyl)-3-fluoro-5-[(propan-2-yl)oxy]benzohydrazide
-
N'-(2,6-difluorobenzene-1-sulfonyl)-3-methoxy-5-[(propan-2-yl)oxy]benzohydrazide
-
N'-(2,6-difluorobenzene-1-sulfonyl)-3-methyl-5-[(propan-2-yl)oxy]benzohydrazide
-
N'-(2-dluorobenzoyl)-4-methylbenzenesulfonohydrazide
-
N'-(2-fluoro-3-(trifluoromethyl)benzoyl)-benzenesulfonohydrazide
-
N'-(2-fluoro-3-(trifluoromethyl)benzoyl)naphthalene-2-sulfonohydrazide
-
N'-(2-fluoro-3-methoxybenzoyl)benzenesulfonohydrazide
-
N'-(2-fluoro-3-methyl-5-((2-methylallyl)oxy)benzoyl)-benzenesulfonohydrazide
-
N'-(2-fluoro-3-methyl-5-((2-methylallyl)oxy)benzoyl)benzenesulfonohydrazide
-
N'-(2-fluoro-3-methyl-5-(1H-pyrazol-1-yl)benzoyl)benzenesulfonohydrazide
-
N'-(2-fluoro-3-methyl-5-(2H-1,2,3-triazol-2-yl)benzoyl)-naphthalene-2-sulfonohydrazide
-
N'-(2-fluoro-3-methyl-5-(3-methyl-1H-pyrazol-1-yl)benzoyl)-benzenesulfonohydrazide
-
N'-(2-fluoro-3-methyl-5-(3-methyl-1H-pyrazol-1-yl)benzoyl)benzenesulfonohydrazide
-
N'-(2-fluoro-3-methyl-5-(4-methyl-1H-pyrazol-1-yl)benzoyl)-benzenesulfonohydrazide
-
N'-(2-fluoro-3-methyl-5-(4-methyl-1H-pyrazol-1-yl)benzoyl)benzenesulfonohydrazide
-
N'-(2-fluoro-3-methyl-5-(5-methyl-1H-pyrazol-1-yl)benzoyl)benzenesulfonohydrazide
-
N'-(2-fluoro-3-methylbenzoyl)benzenesulfonohydrazide
-
N'-(2-fluoro-3-methylbenzoyl)naphthalene-2-sulfonohydrazide
-
N'-(2-fluoro-5-(1H-pyrazol-1-yl)benzoyl)benzenesulfonohydrazide
-
N'-(2-fluoro-5-(2H-1,2,3-triazol-2-yl)benzoyl)benzenesulfonohydrazide
-
N'-(2-fluoro-5-(3-methyl-1H-pyrazol-1-yl)benzoyl)benzenesulfonohydrazide
-
N'-(2-fluoro-5-(4-fluoro-1H-pyrazol-1-yl)-3-methylbenzoyl)benzenesulfonohydrazide
-
N'-(2-fluoro-5-(4-methyl-1H-pyrazol-1-yl)benzoyl)benzenesulfonohydrazide
-
N'-(2-fluoro-5-(furan-2-yl)-3-methylbenzoyl)benzenesulfonohydrazide
-
N'-(2-fluoro-5-(furan-2-yl)benzoyl)benzenesulfonohydrazide
-
N'-(2-fluoro-5-(pyridin-2-yl)benzoyl)benzenesulfonohydrazide
-
N'-(2-fluoro-5-isopropoxy-3-methylbenzoyl)benzenesulfonohydrazide
-
N'-(2-fluoro-5-isopropoxybenzoyl)benzenesulfonohydrazide
-
N'-(2-fluoro-5-methylbenzoyl)naphthalene-2-sulfonohydrazide
-
N'-(2-fluoro-5-propoxybenzoyl)benzenesulfonohydrazide
-
N'-(2-fluorobenzene-1-sulfonyl)-3-(furan-2-yl)-5-methoxybenzohydrazide
-
N'-(2-fluorobenzene-1-sulfonyl)-3-(furan-2-yl)-5-methylbenzohydrazide
-
N'-(2-fluorobenzene-1-sulfonyl)-3-(naphthalen-2-yl)benzohydrazide
-
N'-(2-fluorobenzene-1-sulfonyl)-3-(pyrimidin-2-yl)benzohydrazide
-
N'-(2-fluorobenzene-1-sulfonyl)-3-(pyrimidin-4-yl)benzohydrazide
-
N'-(2-fluorobenzene-1-sulfonyl)-3-(trifluoromethoxy)benzohydrazide
-
N'-(2-fluorobenzene-1-sulfonyl)-3-methoxy-5-(pyridin-2-yl)benzohydrazide
-
N'-(2-fluorobenzene-1-sulfonyl)-3-methyl-5-(pyridin-2-yl)benzohydrazide
-
N'-(2-fluorobenzene-1-sulfonyl)-3-methyl-5-(pyrimidin-2-yl)benzohydrazide
-
N'-(2-fluorobenzene-1-sulfonyl)benzohydrazide
-
N'-(2-fluorobenzoyl)-2-methoxybenzenesulfonohydrazide
-
N'-(2-fluorobenzoyl)-2-methylbenzenesulfonohydrazide
-
N'-(2-fluorobenzoyl)-3-methoxybenzenesulfonohydrazide
-
N'-(2-fluorobenzoyl)-3-methylbenzenesulfonohydrazide
-
N'-(2-fluorobenzoyl)-4-methoxybenzenesulfonohydrazide
-
N'-(2-methoxybenzoyl)naphthalene-2-sulfonohydrazide
-
N'-(2-methylbenzoyl)naphthalene-2-sulfonohydrazide
-
N'-(2-phenylisonicotinoyl)benzenesulfonohydrazide
-
N'-(3-(1,2,4-oxadiazol-3-yl)benzoyl)-2-fluorobenzenesulfonohydrazide
-
N'-(3-(1,3,4-oxadiazol-2-yl)benzoyl)-2-fluorobenzenesulfonohydrazide
-
N'-(3-(1H-pyrazol-1-yl)benzoyl)-2-fluorobenzenesulfonohydrazide
-
N'-(3-(1H-pyrazol-1-yl)benzoyl)benzenesulfonohydrazide
N'-(3-(3,5-dimethyl-1H-pyrazol-1-yl)benzoyl)-2-fluorobenzenesulfonohydrazide
-
N'-(3-(4-fluoro-1H-pyrazol-1-yl)-5-methylbenzoyl)benzenesulfonohydrazide
-
N'-(3-(allyloxy)-5-fluorobenzoyl)-2-fluorobenzenesulfonohydrazide
-
N'-(3-(allyloxy)-5-methylbenzoyl)-2-fluorobenzenesulfonohydrazide
-
N'-(3-(allyloxy)benzoyl)-2-fluorobenzenesulfonohydrazide
-
N'-(3-(cyclopentyloxy)benzoyl)-2-fluorobenzenesulfonohydrazide
-
N'-(3-(cyclopentyloxy)benzoyl)benzenesulfonohydrazide
-
N'-(3-(cyclopropylmethoxy)-5-fluorobenzoyl)-2-fluorobenzenesulfonohydrazide
-
N'-(3-(cyclopropylmethoxy)-5-methylbenzoyl)-2-fluorobenzenesulfonohydrazide
-
N'-(3-(cyclopropylmethoxy)benzoyl)-2-fluorobenzenesulfonohydrazide
-
N'-(3-(ethoxymethyl)-5-methylbenzoyl)-2-fluorobenzenesulfonohydrazide
-
N'-(3-(furan-2-yl)-5-methoxybenzoyl)benzenesulfonohydrazide
-
N'-(3-(furan-2-yl)-5-methylbenzoyl)benzenesulfonohydrazide
-
N'-(3-(piperazin-1-yl)benzoyl)benzenesulfonohydrazide
-
N'-(3-(pyridin-2-yl)benzoyl)benzenesulfonohydrazide
-
N'-(3-(pyridin-3-yl)benzoyl)benzenesulfonohydrazide
-
N'-(3-(pyrimidin-2-yl)benzoyl)benzenesulfonohydrazide
-
N'-(3-(pyrimidin-5-yl)benzoyl)benzenesulfonohydrazide
N'-(3-(thiazol-2-yl)benzoyl)benzenesulfonohydrazide
-
N'-(3-(thiazol-4-yl)benzoyl)benzenesulfonohydrazide
-
N'-(3-(thiophen-2-yl)benzoyl)benzenesulfonohydrazide
-
N'-(3-(thiophen-3-yl)benzoyl)benzenesulfonohydrazide
-
N'-(3-(trifluoromethoxy)benzoyl)benzenesulfonohydrazide
-
N'-(3-(trifluoromethoxy)benzoyl)naphthalene-2-sulfonohydrazide
-
N'-(3-(trifluoromethyl)benzoyl)benzenesulfonohydrazide
-
N'-(3-(trifluoromethyl)benzoyl)naphthalene-2-sulfonohydrazide
-
N'-(3-acetylbenzoyl)naphthalene-2-sulfonohydrazide
-
N'-(3-aminobenzoyl)naphthalene-2-sulfonohydrazide
-
N'-(3-bromobenzoyl)-2-fluorobenzenesulfonohydrazide
-
N'-(3-butoxybenzoyl)-2-fluorobenzenesulfonohydrazide
-
N'-(3-butoxybenzoyl)benzenesulfonohydrazide
-
N'-(3-chloro-2-fluorobenzoyl)benzenesulfonohydrazide
-
N'-(3-chloro-2-fluorobenzoyl)naphthalene-2-sulfonohydrazide
-
N'-(3-chloro-5-(furan-2-yl)benzoyl)-2-fluorobenzenesulfonohydrazide
-
N'-(3-chloro-5-(furan-2-yl)benzoyl)benzenesulfonohydrazide
-
N'-(3-chloro-5-(thiophen-2-yl)benzoyl)-2-fluorobenzenesulfonohydrazide
-
N'-(3-cyanobenzoyl)naphthalene-2-sulfonohydrazide
-
N'-(3-cyclopropoxy-5-methylbenzoyl)-2-fluorobenzenesulfonohydrazide
-
N'-(3-ethoxy-5-fluorobenzoyl)-2-fluorobenzenesulfonohydrazide
-
N'-(3-ethoxy-5-methoxybenzoyl)-2-fluorobenzenesulfonohydrazide
-
N'-(3-ethoxy-5-methylbenzoyl)-2,3-difluorobenzenesulfonohydrazide
-
N'-(3-ethoxy-5-methylbenzoyl)-2,4-difluorobenzenesulfonohydrazide
-
N'-(3-ethoxy-5-methylbenzoyl)-2,5-difluorobenzenesulfonohydrazide
-
N'-(3-ethoxy-5-methylbenzoyl)-2,6-difluorobenzenesulfonohydrazide
-
N'-(3-ethoxy-5-methylbenzoyl)-2-fluoro-3-methylbenzenesulfonohydrazide
-
N'-(3-ethoxy-5-methylbenzoyl)-2-fluoro-4-methylbenzenesulfonohydrazide
-
N'-(3-ethoxy-5-methylbenzoyl)-2-fluoro-5-methylbenzenesulfonohydrazide
-
N'-(3-ethoxy-5-methylbenzoyl)-2-fluorobenzenesulfonohydrazide
-
N'-(3-ethoxybenzoyl)-2-fluoro-5-methoxybenzenesulfonohydrazide
-
N'-(3-ethoxybenzoyl)-2-fluoro-6-methoxybenzenesulfonohydrazide
-
N'-(3-ethoxybenzoyl)-2-fluorobenzenesulfonohydrazide
-
N'-(3-ethoxybenzoyl)benzenesulfonohydrazide
-
N'-(3-ethoxybenzoyl)naphthalene-2-sulfonohydrazide
-
N'-(3-ethyl-2-fluorobenzoyl)benzenesulfonohydrazide
-
N'-(3-ethyl-2-fluorobenzoyl)naphthalene-2-sulfonohydrazide
-
N'-(3-ethylbenzoyl)-2-fluorobenzenesulfonohydrazide
-
N'-(3-ethylbenzoyl)benzenesulfonohydrazide
-
N'-(3-fluoro-5-(1H-pyrazol-1-yl)benzoyl)benzenesulfonohydrazide
-
N'-(3-fluoro-5-(3-methyl-1H-pyrazol-1-yl)benzoyl)benzenesulfonohydrazide
-
N'-(3-fluoro-5-(4-methyl-1H-pyrazol-1-yl)benzoyl)benzenesulfonohydrazide
-
N'-(3-fluoro-5-(furan-2-yl)benzoyl)benzenesulfonohydrazide
-
N'-(3-fluoro-5-(pyridin-2-yl)benzoyl)benzenesulfonohydrazide
-
N'-(3-fluoro-5-propoxybenzoyl)benzenesulfonohydrazide
-
N'-(3-fluorobenzoyl)naphthalene-2-sulfonohydrazide
-
N'-(3-isobutoxybenzoyl)benzenesulfonohydrazide
-
N'-(3-isopropoxybenzoyl)benzenesulfonohydrazide
-
N'-(3-isopropylbenzoyl)benzenesulfonohydrazide
-
N'-(3-isopropylbenzoyl)naphthalene-2-sulfonohydrazide
-
N'-(3-methoxy-5-(1H-pyrazol-1-yl)benzoyl)-benzenesulfonohydrazide
-
N'-(3-methoxy-5-(1H-pyrazol-1-yl)benzoyl)benzenesulfonohydrazide
-
N'-(3-methoxy-5-(pyridin-2-yl)benzoyl)benzenesulfonohydrazide
-
N'-(3-methoxybenzoyl)naphthalene-2-sulfonohydrazide
-
N'-(3-methoxylbenzoyl)naphthalene-2-sulfonohydrazide
-
N'-(3-methylbenzoyl)benzenesulfonohydrazide
-
N'-(3-phenoxybenzoyl)benzenesulfonohydrazide
-
N'-(3-propoxybenzoyl)benzenesulfonohydrazide
-
N'-(3-propoxybenzoyl)naphthalene-2-sulfonohydrazide
-
N'-(3-propylbenzoyl)benzenesulfonohydrazide
-
N'-(4-(trifluoromethoxy)benzoyl)naphthalene-2-sulfonohydrazide
-
N'-(4-cyanobenzoyl)naphthalene-2-sulfonohydrazide
-
N'-(4-fluoro-5-methyl-[1,1'-biphenyl]-3-carbonyl)-benzenesulfonohydrazide
-
N'-(4-fluoro-[1,1'-biphenyl]-3-carbonyl)-benzenesulfonohydrazide
-
N'-(4-fluorobenzoyl)naphthalene-2-sulfonohydrazide
-
N'-(4-methoxybenzoyl)naphthalene-2-sulfonohydrazide
-
N'-(4-methylbenzoyl)naphthalene-2-sulfonohydrazide
-
N'-(5-(allyloxy)-2-fluoro-3-methylbenzoyl)-benzenesulfonohydrazide
-
N'-(5-(allyloxy)-2-fluoro-3-methylbenzoyl)benzenesulfonohydrazide
-
N'-(5-(allyloxy)-2-fluorobenzoyl)benzenesulfonohydrazide
-
N'-(5-(cyclopropylmethoxy)-2-fluoro-3-methylbenzoyl)-benzenesulfonohydrazide
-
N'-(5-(cyclopropylmethoxy)-2-fluoro-3-methylbenzoyl)benzenesulfonohydrazide
-
N'-(5-(ethoxymethyl)-2-fluoro-3-methylbenzoyl)-benzenesulfonohydrazide
-
N'-(5-(ethoxymethyl)-2-fluoro-3-methylbenzoyl)benzenesulfonohydrazide
-
N'-(5-chloro-4-fluoro-[1,1'-biphenyl]-3-carbonyl)-benzenesulfonohydrazide
-
N'-(5-ethoxy-2-fluoro-3-methylbenzoyl)-2-fluorobenzenesulfonohydrazide
-
N'-(5-ethoxy-2-fluoro-3-methylbenzoyl)naphthalene-2-sulfonohydrazide
-
N'-(5-ethoxy-2-fluorobenzoyl)benzenesulfonohydrazide
-
N'-(5-phenylnicotinoyl)benzenesulfonohydrazide
-
N'-(6-phenylpicolinoyl)benzenesulfonohydrazide
-
N'-(benzenesulfonyl)-2-fluoro-3-methyl-5-(pyridin-2-yl)benzohydrazide
-
N'-(benzenesulfonyl)-2-fluoro-3-methyl-5-(pyrimidin-2-yl)benzohydrazide
-
N'-(benzenesulfonyl)-2-fluoro-3-methyl-5-[(propan-2-yl)oxy]benzohydrazide
-
N'-(benzenesulfonyl)-2-fluoro-5-(pyridazin-4-yl)benzohydrazide
-
WM-2474
N'-(benzenesulfonyl)-2-fluoro-5-(pyrimidin-2-yl)benzohydrazide
-
N'-(benzenesulfonyl)-2-fluoro-5-(pyrimidin-4-yl)benzohydrazide
-
N'-(benzenesulfonyl)-2-fluoro-5-[(prop-2-yn-1-yl)oxy]benzohydrazide
-
N'-(benzenesulfonyl)-3-fluoro-5-(pyrimidin-2-yl)benzohydrazide
-
N'-(benzenesulfonyl)-3-fluorobenzohydrazide
-
N'-(benzenesulfonyl)-3-methoxy-5-(pyrimidin-2-yl)benzohydrazide
-
N'-(benzenesulfonyl)-3-methoxybenzohydrazide
-
N'-(benzenesulfonyl)-3-methyl-5-(pyrimidin-2-yl)benzohydrazide
-
N'-(benzenesulfonyl)-4-fluoro-5-methyl[1,1'-biphenyl]-3-carbohydrazide
N'-(benzenesulfonyl)-5-chloro-4-fluoro[1,1'-biphenyl]-3-carbohydrazide
-
N'-(ethoxy-2-fluoro-3-methylbenzoyl)-benzenesulfonohydrazide
-
N'-(ethoxy-2-fluoro-3-methylbenzoyl)benzenesulfonohydrazide
-
N'-(naphthalen-2-ylsulfonyl)benzohydrazide
-
N'-(naphthalene-2-sulfonyl)benzohydrazide
-
N'-([1,1'-biphenyl]-3-carbonyl)-2-fluorobenzenesulfonohydrazide
-
N'-([1,1'-biphenyl]-3-carbonyl)benzenesulfonohydrazide
-
N'-([1,1'-biphenyl]-3-carbonyl)naphthalene-2-sulfonohydrazide
-
N'-benzoylbenzenesulfonohydrazide
-
N'-[(3-bromophenyl)sulfonyl]-2-fluorobenzohydrazide
-
N'-[(3-ethylphenyl)sulfonyl]-2-fluorobenzohydrazide
-
N'-[(4-bromophenyl)sulfonyl]-2-fluorobenzohydrazide
-
N-(2-fluoro-3-methyl-5-(2H-1,2,3-triazol-2-yl)benzoyl)benzenesulfonohydrazide
-
N-(2-fluoro-3-methyl-5-propoxybenzoyl)-benzenesulfonohydrazide
-
N-(2-fluoro-3-methyl-5-propoxybenzoyl)benzenesulfonohydrazide
-
N-(2-fluoro-4-[[(1-hydroxy-3-methylbenzo[f]quinazolin-9-yl)methyl]amino]benzoyl)-L-glutamic acid
-
N-(3-aminopropyl)acetamido-CoA
-
-
N-(3-benzamidobutyl)acetamido-CoA
-
-
N-(3-benzamidopentyl)acetamido-CoA
-
-
N-(3-benzamidopropyl)acetamido-CoA
-
-
N-(3-[[(2,2-dimethylpropanoyl)oxy]amino]propyl)acetamido-CoA
-
-
N-(4-acetyl-2-methyl-3,4-dihydro-2H-1,4-benzothiazine-7-sulfonyl)benzamide
-
-
N-(4-chloro-3-trifluoromethyl-phenyl)-2-ethoxy-6-pentadecyl-benzamide
-
-
N-(4-chlorophenyl)-2-(4,6-dimethyl-3-oxo[1,2]thiazolo[5,4-b]pyridin-2(3H)-yl)acetamide
-
-
N-(4-cyano-3-(trifluoromethyl)phenyl)-2-decyl-6-ethoxybenzamide
-
inhibits human p300 recombinant enzyme similar to anacardic acid
N-(4-cyano-3-(trifluoromethyl)phenyl)-2-ethoxy-6-octylbenzamide
-
inhibits human p300 recombinant enzyme similar to anacardic acid, moreover this inhibitor induces significant apoptosis at 0.05 nM in U937 leukemia cells
N-(4-[[(1-hydroxy-3-methylbenzo[f]quinazolin-9-yl)methyl]amino]cyclohexane-1-carbonyl)-L-glutamic acid
-
N-(4-[[(2,2-dimethylpropanoyl)oxy]amino]butyl)acetamido-CoA
-
-
N-(4-[[(2-amino-4-hydroxyquinazolin-6-yl)methyl](formyl)amino]benzoyl)-L-glutamic acid
-
N-(4-[[(2-amino-4-oxo-3,4-dihydroquinazolin-6-yl)methyl](cyanomethyl)amino]benzoyl)-L-glutamic acid
ZINC29250560
N-(4-[[(2-amino-4-oxo-3,4-dihydroquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino]benzoyl)-L-glutamic acid
N-(4-[[(2-amino-7-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino]benzoyl)-L-glutamic acid
-
N-(4-[[4-(2-amino-6-oxo-1,6-dihydropyrimidin-5-yl)benzene-1-sulfonyl]amino]benzoyl)-L-glutamic acid
-
N-(5-[[(2,2-dimethylpropanoyl)oxy]amino]pentyl)acetamido-CoA
-
-
N-benzyl-2,4-dimethyl-3,4-dihydro-2H-1,4-benzothiazine-7-sulfonamide
-
-
N-benzyl-2-methyl-4-(phenylacetyl)-3,4-dihydro-2H-1,4-benzothiazine-7-sulfonamide
-
-
N-benzyl-4-(chloroacetyl)-2-methyl-3,4-dihydro-2H-1,4-benzothiazine-7-sulfonamide
-
-
N-benzyl-4-(cyclohexanecarbonyl)-2-methyl-3,4-dihydro-2H-1,4-benzothiazine-7-sulfonamide
-
-
N-benzyl-4-(cyclopropanecarbonyl)-2-methyl-3,4-dihydro-2H-1,4-benzothiazine-7-sulfonamide
-
-
N-benzylacetamido-CoA
-
-
N-ethylmaleimide
N-[(1S)-1-cyclopropyl-2,2,2-trifluoroethyl]-N-[(4-fluorophenyl)methyl]-2-[(1R)-5-[(methylcarbamoyl)amino]-2',4'-dioxo-2,3-dihydrospiro[indene-1,5'-[1,3]oxazolidin]-3'-yl]acetamide
-
-
N-[(2-chloro-6-fluorophenyl)methyl]-2-(2,5-dioxo-4-phenyl-4-propylimidazolidin-1-yl)-N-methylacetamide
-
-
N-[(3S)-5-[[(1S)-3-(5-[[(5S)-5-(3-carbamimidamidopropyl)-3,6-dioxopiperazin-2-yl]methyl]-2-hydroxyphenoxy)-1-carboxypropyl]amino]-3-carboxy-3-hydroxy-5-oxopentanoyl]-L-aspartic acid
-
NK13650A
N-[(4-fluorophenyl)methyl]-2-[(1R)-5-[(methylcarbamoyl)amino]-2',4'-dioxo-2,3-dihydrospiro[indene-1,5'-[1,3]oxazolidin]-3'-yl]-N-[(2S)-1,1,1-trifluoropropan-2-yl]acetamide
N-[2-(2,5-dimethoxybenzoyl)-3-methyl-1-benzofuran-6-yl]-3,5-dimethoxybenzamide
-
F2209-0381
N-[2-(S-Coenzyme A)acetyl]spermidine amide
-
strong
N-[4-([[(6S)-2-amino-5-methyl-4-oxo-3,4,5,6,7,8-hexahydropteridin-6-yl]methyl]amino)benzoyl]-L-glutamic acid
ZINC34633488
N-[4-chloro-3-(trifluoromethyl)phenyl]-2-ethoxy-6-tetradecylbenzamide
-
-
N-[4-cyano-3-(trifluoromethyl)phenyl]-2-ethoxy-6-heptylbenzamide
-
-
N-[4-[(2-methyl-4-oxo-3,4-dihydroquinazoline-6-sulfonyl)amino]benzoyl]-L-glutamic acid
-
N-[5-[(5-[[5-([4-[(5-[[5-([5-[(5-[[3-(dimethylamino)propyl]carbamoyl]-1-methyl-1H-pyrrol-3-yl)carbamoyl]-1-methyl-1H-pyrrol-3-yl]carbamoyl)-1-methyl-1H-pyrrol-3-yl]carbamoyl]-1-methyl-1H-pyrrol-3-yl)amino]-4-oxobutyl]carbamoyl)-1-methyl-1H-pyrrol-3-yl]carbamoyl]-1-methyl-1H-pyrrol-3-yl)carbamoyl]-1-methyl-1H-pyrrol-3-yl]-4-[(N-[[2-(2-[4-[(4Z)-4-[[5-(2,3-dimethyl-6-nitrophenyl)furan-2-yl]methylidene]-3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl]benzamido]ethoxy)ethoxy]acetyl]-beta-alanyl)amino]-1-methyl-1H-pyrrole-2-carboxamide
-
N6-Acetyllysine
-
competitive
naphthoquinone
-
-
NSC694616
-
NU9056
p-chloromercuribenzoate
palmatine
-
-
peptide conjugate Boc-C5-CoA
peptide Boc-C5-CoA, the molecule exploits an additional electron-rich pocket (P2) about 10 A away from the lysine binding pocket (P1). Boc-C5-CoA that shows high affinity for, comprises a CoA moiety which binds to the P1 pocket, a 1,5-pentanediamine linker and a tert-butoxycarbonyl cap, which is accommodated by the P2 pocket. CoA is connected to the N1 of the linker through a carboxymethylene bridge, while the tert-butoxycarbonyl cap protects the N5
-
peptide conjugate H3-CoA-20
peptide H3-CoA-20 resembles the K14-containing sequence of histone H3, the main substrate of PCAF, R1 is A-P-R-K-Q-L-OH and R2 is G-G-T-S-L-R-A-T-Q-K-T-R-A-NHCH3
-
peptide conjugate H4-K16-CoA
peptide H4-K16-CoA, R1 is K-A-G-G-K-G-L-G-K-G-G-K-G-R-G-S-OCH3 and R2 is R-H-R-K-NH2; peptide H4-K16-CoA, R1 is K-A-G-G-K-G-L-G-K-G-G-K-G-R-G-S-OCH3 and R2 is R-H-R-K-NH2
-
Plumbagin
Polyarginine
-
-
Polyglutamic acid
-
-
potassium phosphate
-
90 mM
procyanidin B1
-
-
procyanidin B2
-
-
procyanidin B3
-
-
Prostaglandin A2
-
-
Prostaglandin B2
-
-
prostaglandin J2
-
-
prostaglandin K2
-
-
protein HBZ
-
S-(4-benzylpiperazin-1-yl)(1-oxo)ethyl-CoA
-
-
S-(piperazin-1-yl)(1-oxo)ethyl-CoA
-
-
S-(tert-butyl 4-acetylpiperazin-1-yl)(1-oxo)ethyl-CoA
-
-
Sea urchin sperm chromatin
-
-
-
siRNA
-
silencing of enzyme gene
-
sodium 4-[3,5-bis[(E)-2-(4-hydroxy-3-methoxyphenyl)ethenyl]-1H-pyrazol-1-yl]benzoate
-
CTK7A
Spd(N1)-CoA
obtained by linking the polyamine spermidine to CoA using a carboxymethylene bridge
spermidine
-
inhibits histone acetylation at high concentrations, enzyme forms A and B
spermidine-CoA
-
-
spinosine
-
-
taxodione
-
-
tert-butyl-(3-(2-(naphthalen-2-ylsulfono)hydrazinecarbonyl)-phenyl)carbamate
-
tetradecylidenepropanedioic acid
-
EML264
thiazole
-
-
tridecylidenepropanedioic acid
-
-
Triton X-100
Valproic acid
-
venenatine
-
-
WM-8014
highly potent inhibitor, competitive inhibition with respect to acetyl-CoA
[(3,7-dimethyloctyl)oxy]benzene
-
-
[5-(4-[[(2-phenylethyl)(4-[4-[(pyrrolidin-1-yl)methyl]phenoxy]butyl)amino]methyl]phenyl)-2H-tetrazol-2-yl]acetic acid
-
TH1834
[histone H4]-L-lysine12-CoA
bisubstrate inhibitor, i.e. Ac-SGRGKGGKGLGK(CoA)GGAKRHRK, competitive inhibition with respect to both acetyl-CoA and histone H4, highly specific inhibitor for histone acetyltransferase 1
-
[histone H4]-L-lysine16-CoA
-
[histone H4]-L-lysine5-CoA
bisubstrate inhibitor, i.e. Ac-SGRGK(CoA)GGKGLGKGGAKRHRK
-
[histone H4]-L-lysine8-CoA
bisubstrate inhibitor, i.e. Ac-SGRGKGGK(CoA)GLGKGGAKRHRK
-
additional information
-